Voluntary Vs Statutory: Pharma Firms Soon To Choose Between Two UK Pricing Schemes

The UK’s new voluntary drug pricing and access deal is a “paradigm shift” that will see companies paying different levels of rebates depending on their product mix, with higher payments on older medicines making headroom for growth in newer drugs, according to one lawyer.